Brain metabolic decreases related to the close of the ApoE e4 allele in Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 75, Issue 3, 2004, Pages 370-376

  Mosconi, L ^a   Nacmias, B ^a   Sorbi, S ^a   De Cristofaro, M T R ^a   Fayazz, M ^a   Tedde, A ^a   Bracco, L ^a   Herholz, K ^b   Pupi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; GLUCOSE;

ADULT; AGE; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; BRAIN METABOLISM; CONTROLLED STUDY; DATA BASE; DEMENTIA; DIAGNOSTIC IMAGING; DISEASE DURATION; DISEASE SEVERITY; FEMALE; GENDER; GENOTYPE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; LIMBIC CORTEX; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; STANDARDIZATION; STATISTICAL SIGNIFICANCE;

AGED; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BRAIN; CASE-CONTROL STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; GENE DOSAGE; GENETIC PREDISPOSITION TO DISEASE; GLUCOSE; HUMANS; MALE; PHENOTYPE; RADIOPHARMACEUTICALS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 1542407369     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2003.014993     Document Type: Article

References (38)

1. St George-Hyslop PH. Molecular genetics of Alzheimer's Disease. Biol Psychiatry 2001;47:183-99.
2. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991;41:479-86.
3. Poirier J, Delisle MC, Quirion R, et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci USA 1995;92:12260-4.
4. Nobili F, Koulibaly M, Vitali P, et al. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors. J Nucl Med 2002;43:983-90.
5. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 1995;273:942-7.
6. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996;334:752-8.
7. de Leon MJ, Convit A, Wolf OT, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001;98:10966-71.
8. Herholz K, Salmon E, Perani D, et al. Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. NeuroImage 2002;17:302-16.
9. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997;278:1349-56.
10. Roses AD. Apolipoprotein E and Alzheimer's disease. The tip of the susceptibility iceberg. Ann NY Acad Sci 1998;855:738-43.
11. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of alipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
12. Poirier J, Davignon J, Bouthillier D, et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993;342:697-9.
13. Small GW, Ercoli LM, Silverman DH, et al. Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 2000;97:6037-42.
14. Reiman EM, Caselli RJ, Chen K, et al. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:3334-9.
15. Lehtovirta M, Soininen H, Laakso MP, et al. SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatry 1996;60:644-9.
16. Lehtovirta M, Kuikka J, Helisalmi S, et al. Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998;64:742-6.
17. Corder EH, Jelic V, Basun H, et al. No difference in cerebral glucose metabolism in patients with Alzheimer's disease and differing apoliprotein E genotypes. Arch Neurol 1997;54:273-7.
18. Hirono N, Mori E, Yasuda M, et al. Lack of association of apoliprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer's disease. Alzheimer Dis Assoc Disord 1998;12:362-7.
19. van Dyck CH, Gelernter J, MacAvoy MG, et al. Absence of an apoliprotein E epsilon4 allele is associated with increased parietal regional cerebral blood flow asymmetry in Alzheimer's disease. Arch Neurol 1998;55:1460-6.
20. Hirono N, Hashimoto M, Yasuda M, et al. The effect of APOE E4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002;58:743-50.
21. Friston KJ, Frith CD, Liddle PF, et al. Comparing functional (PET) images: the assessment of significant change. J Cereb Blood Flow Metab 1991;11:690-9.
22. Minoshima S, Koeppe RA, Frey KA, et al. Anatomical standardization: linear scaling and non linear warping of functional brain images. J Nucl Med 1994;35:1528-37.
23. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of NINCDS/ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984;34:939-44.
24. Sorbi S, Nacmias B, Forleo P, et al. Alzheimer's disease and apolipoprotein E in Italy. Ann NY Acad Sci 1996;777:260-5.
25. Bartenstein P, Asenbaum S, Catafau A, et al. European Association of Nuclear Medicine procedure guidelines for brain imaging using [(18)F]FDG. Eur J Nucl Med Mol Imaging 2002;29:43-8.
26. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci 1978;25:638-43.
27. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain: 3-dimensional proportional system - an approach to cerebral imaging. New York: Thieme Medical Publishers, 1988.
28. Lancaster JL, Woldorff MG, Parsons LM, et al. Automated Talairach Atlas labels for functional brain mapping. Human Brain Mapp 2000;10:120-31.
29. Johnson KA, Jones BL, Holman JA, et al. Predinical prediction of Alzheimer's disease using SPECT. Neurology 1998;50:1563-71.
30. Matsuda H, Kitayama N, Ohnishi T, et al. Longitudinal evaluation of both morphologic and functional changes in the same individuals with Alzheimer's disease. J Nucl Med, 2002;43:304-11.
31. Chetelat G, Baron JC. Early diagnosis of alzheimer's disease: contribution of structural neuroimaging. Neuroimage 2003;18:525-41.
32. Corbetta M, Miezin FM, Dobmeyer S, et al. Selective and divided attention during visual discriminations of shape, color, and speed: functional anatomy by positron emission tomography. J Neurosci 1991;11:2383-402.
33. Levine B, Cabeza R, McIntosh AR, et al. Functional reorganisation of memory after traumatic brain injury: a study with H(2)(15)0 positron emission tomography. J Neural Neurosurg Psychiatry 2002;73:173-81.
34. Helkala EL, Koivisto K, Hanninen T, et al. Memory functions in human subjects with different apolipoprotein E phenotypes during a 3-year population-based follow-up study. Neurosci Lett 1996;204:177-80.
35. Craft S, Teri L, Edland SD, et al. Accelerated decline in apoliprotein E-epsilon 4 homozygotes with Alzheimer's disease. Neurology 1998;51:149-53.
36. Caselli RJ, Graff-Radford NR, Reiman EM, et al. Preclinical memory decline in cognitively normal apolipoprotein E-epsilon4 homozygotes. Neurology 1999;53:201-7.
37. Ibanez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer's disease. Neurology 1998;50:1585-93.
38. Mazziotta JC, Phelps ME. Principles and Applications for the brain and heart. In: Phelps ME, Mazziotta JC, Schelbert H, eds. Positron emission tomography and autoradiography. New York: Raven Press, 1986:493-79.